Table 3.
HPV genotypea | HIV-positive (n = 14), n (%) | HIV-negative (n = 31), n (%) | All Women (n = 45), n (%) |
HPV Positive | 8 (57.1) | 11 (35.5) | 19 (42.2) |
HPV Negative | 6 (42.9) | 20 (64.5) | 26 (57.8) |
Single infections | |||
16 | 0 - | 1 (3.2) | 1 (2.2) |
33 | 0 - | 2 (6.4) | 2 (4.4) |
35 | 1 (7.1) | 1 (3.2) | 2 (4.4) |
52 | 1 (7.1) | 0 (3.2) | 1 (2.2) |
58 | 1 (7.1) | 1 (3.2) | 2 (4.4) |
67 | 1 (7.1) | 0 - | 1 (2.2) |
70 | 2 (14.3) | 0 - | 2 (4.4) |
54 | 0 - | 1 (3.2) | 1 (2.2) |
81 | 1 (7.1) | 1 (3.2) | 2 (4.4) |
Total single infections | 7 (50.0) | 7 (22.6) | 14 (31.1) |
Multiple infectionsb | |||
56 (4) + 42 (2) | 1 (7.1) | 0 - | 1 (2.2) |
16 (5) + 42 (3) | 0 - | 1 (3.2) | 1 (2.2) |
31 (2) + 58 (5) + 35 (1) | 0 - | 1 (3.2) | 1 (2.2) |
33 (4) + 54 (2) | 0 - | 1 (3.2) | 1 (2.2) |
70 (9) + 81 (1) | 0 - | 1 (3.2) | 1 (2.2) |
Total multiple infections | 1 (7.1) | 4 (12.9) | 5 (11.1) |
a In bold case HPV genotypes defined by IARC working group as class I carcinogens for humans [5,50].
b HPV genotypes present in multiple infections were characterized by subcloning of MY09/MY11 (two samples) or GP5+/GP6+ (three samples) PCR products and sequencing analysis. Number of clones analyzed for each HPV genotype are given in parenthesis.